Skip to Primary Navigation Skip to Site Navigation Skip to Main Content

3M Licenses Fentanyl Transdermal Patch Technology to STADA Arzneimittel AG

Tuesday, November 19, 2013 12:05 pm CST

Dateline:

ST. PAUL, Minn.
EmailPDFPrintRSS

Public Company Information:

NYSE:
MMM

ST. PAUL, Minn.--(BUSINESS WIRE)--3M Drug Delivery Systems announced today that STADA Arzneimittel AG has become the latest drug company to license 3M’s patented technology directed to a matrix patch for the transdermal delivery of the opioid pain medication fentanyl. Terms of the license agreement were not disclosed.

The 3M Patent (EP 2158905), which was granted on March 20, 2013, enables a transdermal drug delivery device designed to deliver a therapeutically effective amount of fentanyl across the skin of a patient. The matrix device is configured by incorporating fentanyl into an adhesive matrix made of a copolymer containing alkyl acrylate and other monomers.

3M is open to licensing this technology to other interested parties.

About STADA Arzneimittel AG
STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. STADA consistently focuses on a multi-pillar strategy of generics and branded products (OTC) with an increasingly international market orientation. The Group traditionally has a strong presence in Europe and is the only independent generics producer in Germany. Worldwide, STADA is one of the five leading companies in the generics industry and is represented in more than 30 countries with approximately 50 subsidiaries. Branded products such as Mobilat, Grippostad and Ladival are among the highest selling in their product category in Germany. In financial year 2012, STADA achieved Group sales of Euro 1,837.5 million, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of Euro 367.5 million and adjusted net income of Euro 147.9 million. As of December 31, 2012, STADA employed 7,761 people worldwide.

About 3M Drug Delivery Systems
3M Drug Delivery Systems partners with pharmaceutical and biotech companies to develop and manufacture pharmaceutical products using 3M's inhalation, transdermal or microneedle drug delivery technology. 3M offers a full range of feasibility, development and manufacturing capabilities to help bring products to market. Regulatory expertise, quality assurance, operations, marketed product support and other in-house resources are available for each step of the development and commercialization process. For more information, please visit www.3M.com/dds or call 1-800-643-8086.

About 3M
3M captures the spark of new ideas and transforms them into thousands of ingenious products. Our culture of creative collaboration inspires a never-ending stream of powerful technologies that make life better. 3M is the innovation company that never stops inventing. With $30 billion in sales, 3M employs 88,000 people worldwide and has operations in more than 70 countries. For more information, visit www.3M.com or follow @3MNews on Twitter.

3M is a trademark of 3M Company.

Contact:

Karwoski & Courage for 3M
MaryEllen Columbus, 612-342-9705
m.columbus@creativepr.com
or
3M Public Relations & Corporate Communications
Donna Fleming Runyon, 651-736-7646
dlfleming@mmm.com